Gastrointestinal Disorder Therapeutics Market to 2017

Document Sample
Gastrointestinal Disorder Therapeutics Market to 2017 Powered By Docstoc
					        Gastrointestinal Disorder Therapeutics Market to 2017 -
        Crohn's Disease and Irritable Bowel Syndrome Markets
                        Show Strongest Growth
 Reference Code: GBIHC131MR                                                                                        Publication Date: September 2011


Some of the major drugs               GBI Research analysis suggests that the global gastrointestinal disorder therapeutics market is one
in the GERD therapeutics              of the most mature markets in the pharmaceutical industry. Sales in the market are expected to
market, such as Nexium                decline due to various restraints, such as drugs going off-patent, generic substitutions and the
(esomeprazole) and                    availability of alternative therapies. Nevertheless, the global gastrointestinal disorder therapeutics
Aciphex (rabeprazole                  market is an attractive market for the larger pharmaceutical companies.
sodium), are going off-
                                      The Global Gastrointestinal Disorder Therapeutics Market Will Decline due to Patent
patent.
                                      Expiries of Major Drugs in the Market
                                      The global market for gastrointestinal disorder therapeutics will decline in the next seven years due
                                      to the shrinking of the gastroesophageal reflux disease (GERD) therapeutics market. Since the
                                      GERD therapeutics market is the largest market in the gastrointestinal disorders segment, the
                                      negative growth is directly affecting the size of the global gastrointestinal disorder therapeutics
                                      market. Some of the major drugs in the GERD therapeutics market, such as Nexium
                                      (esomeprazole) and Aciphex (rabeprazole sodium), are going off-patent. However, other segments,
                                      namely ulcerative colitis, irritable bowel syndrome and Crohn’s disease, are expected to grow
                                      faster.

                                       Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($bn), 2002-2017

                                                          30



                                                          25
                                                               CAGR (2002-2010): 4.1%                                    CAGR (2010-2017): -4.8%


                                                          20
                                          Revenue ($bn)




                                                          15



                                                          10



                                                          5



                                                          0
                                                                        2002                         2010                            2017

                                       Source: GBI Research, Company Websites




                                      The global gastrointestinal disorder therapeutics market is projected to generate revenues of
                                      approximately $18.3 billion by 2017, after declining at a CAGR (Compounded Annual Growth Rate)
                                      of -4.8% during the period 2010-2017




Gastrointestinal Disorder Therapeutics Market to 2017- Crohn's                                                        GBIHC131MR / Published SEP 2011
Disease and Irritable Bowel Syndrome Markets Show Strongest
Growth                                                                                                                                             Page 1
                                                                                    © GBI Research. This is a licensed product and is not to be photocopied
                                      The Irritable Bowel Syndrome Market is a Fast Growing Market with Strong Pipeline Drugs
                                      with High Safety and Efficacy Profiles
Irritable bowel syndrome              The global gastrointestinal disorder therapeutics market generated approximately $25.8 billion in
is one of the fastest                 2010. The market is anticipated to generate revenues of approximately $18.3 billion by 2017, after
growing therapeutic                   declining at a CAGR of -4.8% between 2010 and 2017. Irritable bowel syndrome is one of the
segments.                             fastest growing therapeutic segments. This growth is primarily attributed to a strong pipeline with
                                      more promising therapies, such as Xifaxan (rifaximin) and Linaclotide (linaclotide acetate). The
                                      expected new drug launches will be priced highly and will capture a major share of prescriptions.
                                      The irritable bowel syndrome market is therefore expected to generate large revenues, with the
                                      increased uptake of these new drugs and increased awareness of the disease among patients
                                      leading to increased treatment seeking rates at the early stages of the disease.
                                      Declining Gastroesophageal Reflux Disease (GERD) Therapeutics Market is Restraining the
                                      Growth of Gastrointestinal Disorder Therapeutics Market
                                      A decline in the annual cost of therapy in the GERD therapeutics market is the principal barrier for
                                      market revenues. Owing to the patent expiries of the major proton pump inhibitors (PPIs) such as
                                      Nexium and Aciphex during the forecast period, the generics market will become increasingly
                                      competitive. The research and development pipeline for GERD therapeutics is weak, owing to the
                                      fact that the market already holds safe and efficient drugs. Most of the drugs in phase III trials are
                                      product extensions and new dosage forms being developed for already approved products.
                                      Therefore, the shrinking of the gastroesophageal reflux disease (GERD) therapeutics market is the
                                      principal cause for the decline in the gastrointestinal disorder therapeutics market.
                                      Steady Increase in Prevalence and Incidence Rates Would Drive the Gastrointestinal
                                      Disorder Therapeutics Market
                                      Gastrointestinal disorders are more prevalent in the elderly population, which implies that the
                                      greater the elderly population is, the greater the diseased population will be. Irritable bowel
                                      syndrome (IBS) has a global prevalence rate in the range of 12-20%. On the other hand,
                                      prevalence of Crohn’s disease is showing a steady increase. The pharmaceutical industry will face
                                      increased demand in the gastrointestinal disorder therapeutic area, driven by the growth of the
                                      diseased population. Moreover, a steady increase in the incidence rate of gastrointestinal disorders
                                      has caused the gastrointestinal disorder pharmaceuticals market to witness significant growth. With
                                      the increasing incidence rates, a greater burden has been laid on the pharmaceutical sector to
                                      develop effective therapeutic approaches to meet the increasing demand. The past decade has
                                      seen a steady increase in the prevalence rates of diseases such as gastroesophageal reflux
                                      disease (GERD). This, in turn, is going to aid the growth of the gastrointestinal disorder
                                      therapeutics market.




Gastrointestinal Disorder Therapeutics Market to 2017- Crohn's                                             GBIHC131MR / Published SEP 2011
Disease and Irritable Bowel Syndrome Markets Show Strongest
Growth                                                                                                                                  Page 2
                                                                         © GBI Research. This is a licensed product and is not to be photocopied
                                      Increasing R&D in Gastrointestinal Disorders Segment Boosts a Strong Clinical Pipeline

                                       Gastrointestinal Disorder Therapeutics Market, Global, Pipeline Molecules by Phase, (%),
                                       2011


                                                                                                        Preclinical
                                                                 Others                                    21%
                                                                  27%




                                                                                                                 Phase I
                                                                                                                  10%




                                                                                Phase II
                                                                                 42%

                                       Source: GBI Research, Company Websites




                                      In the gastrointestinal sector, most companies co-ordinate their research and development (R&D)
                                      activities in order to constantly expand their product pipelines with innovative drugs. Although there
                                      is a consistent and continuous threat from generics and other alternatives, companies in the
                                      gastrointestinal disorders sector are not reluctant to invest in R&D and are focused on offering new
                                      products to the market. There are more than 185 drugs in the gastrointestinal disorders pipeline.
                                      Phase II has the most pipeline drugs, accounting for 42% of the pipeline. Furthermore, the
                                      gastrointestinal pipeline consists of a considerable number of promising biologics at both the phase
                                      III and new drug application (NDA) stages, which are forecast to earn good revenues and capture a
                                      greater market share in the future.




Gastrointestinal Disorder Therapeutics Market to 2017- Crohn's                                                GBIHC131MR / Published SEP 2011
Disease and Irritable Bowel Syndrome Markets Show Strongest
Growth                                                                                                                                     Page 3
                                                                            © GBI Research. This is a licensed product and is not to be photocopied
                                      1         Table of Contents
                                      1   Table of Contents ........................................................................................................................ 4
                                          1.1    List of Tables..................................................................................................................... 8
                                          1.2    List of Figures ................................................................................................................. 11
                                      2   Gastrointestinal Disorder Therapeutics Market: Introduction ..................................................... 13
                                          2.1    Overview ......................................................................................................................... 13
                                          2.2    GBI Research Report Guidance ..................................................................................... 14
                                      3   Global Gastrointestinal Disorder Therapeutics Market: Market Characterization ...................... 15
                                          3.1    Market Forecasts ............................................................................................................ 15
                                             3.1.1    Revenue .................................................................................................................. 15
                                             3.1.2    Global Generic Share .............................................................................................. 16
                                             3.1.3    Annual Cost of Treatment (ACT) ............................................................................. 17
                                             3.1.4    Treatment Usage Patterns ...................................................................................... 18
                                          3.2    Drivers and Restraints for the Global Gastrointestinal Disorder Therapeutics Market .... 24
                                             3.2.1    Market Drivers ......................................................................................................... 24
                                             3.2.2    Market Restraints .................................................................................................... 25
                                      4   Gastrointestinal Disorder Therapeutics Market: Geographical Landscape ................................ 26
                                          4.1    Revenue Analysis by Geography .................................................................................... 26
                                          4.2    The US ............................................................................................................................ 28
                                             4.2.1    Revenue .................................................................................................................. 28
                                             4.2.2    Annual Cost of Treatment........................................................................................ 29
                                             4.2.3    Treatment Usage Patterns ...................................................................................... 30
                                          4.3    Top Five Countries of Europe ......................................................................................... 32
                                             4.3.1    Revenue .................................................................................................................. 32
                                             4.3.2    Revenue by Country ................................................................................................ 33
                                             4.3.3    Annual Cost of Treatment........................................................................................ 35
                                             4.3.4    Treatment Usage Pattern ........................................................................................ 36
                                          4.4    Japan .............................................................................................................................. 38
                                             4.4.1    Revenue .................................................................................................................. 38
                                             4.4.2    Annual Cost of Treatment........................................................................................ 39
                                             4.4.3    Treatment Usage Patterns ...................................................................................... 40
                                      5   Global Gastrointestinal Disorder Therapeutics Market: Therapeutic Landscape ....................... 42
                                          5.1    Global Irritable Bowel Syndrome Therapeutics Market Forecasts .................................. 42
                                             5.1.1    Introduction .............................................................................................................. 42
                                             5.1.2    Revenue .................................................................................................................. 43
                                             5.1.3    Generic Share ......................................................................................................... 44
                                             5.1.4    Revenue Analysis by Country.................................................................................. 45
                                             5.1.5    Annual Cost of Treatment........................................................................................ 47
                                             5.1.6    Treatment Flow Algorithm ....................................................................................... 48
                                             5.1.7    Treatment Usage Patterns ...................................................................................... 49
                                          5.2    Marketed Products .......................................................................................................... 51
                                             5.2.1    Lotronex .................................................................................................................. 51
                                             5.2.2    Amitiza (Lubiprostone)............................................................................................. 51
                                             5.2.3    Bentyl (Dicyclomine hydrochloride) ......................................................................... 52
                                          5.3    Drivers and Restraints for the IBS Therapeutics Market ................................................. 53
                                             5.3.1    Drivers for the IBS Therapeutics Market.................................................................. 53
                                             5.3.2    Restraints for the IBS Therapeutics Market ............................................................. 53
                                          5.4    Global Ulcerative Colitis Therapeutics Market Forecasts ................................................ 54
                                             5.4.1    Introduction .............................................................................................................. 54
                                             5.4.2    Revenue .................................................................................................................. 55
                                             5.4.3    Generic Share ......................................................................................................... 56
                                             5.4.4    Revenue Analysis by Country.................................................................................. 57
                                             5.4.5    Annual Cost of Treatment........................................................................................ 59
                                             5.4.6    Treatment Flow Algorithm ....................................................................................... 60


Gastrointestinal Disorder Therapeutics Market to 2017- Crohn's                                                                         GBIHC131MR / Published SEP 2011
Disease and Irritable Bowel Syndrome Markets Show Strongest
Growth                                                                                                                                                                        Page 4
                                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                           5.4.7      Treatment Usage Patterns ...................................................................................... 61
                                        5.5     Major Marketed Products ................................................................................................ 64
                                           5.5.1      Asacol ...................................................................................................................... 64
                                           5.5.2      Lialda ....................................................................................................................... 64
                                           5.5.3      Pentasa ................................................................................................................... 64
                                           5.5.4      Apriso ...................................................................................................................... 64
                                           5.5.5      Colazal .................................................................................................................... 64
                                           5.5.6      Remicade ................................................................................................................ 65
                                           5.5.7      Azulfidine ................................................................................................................. 65
                                        5.6     Drivers and Restraints for Ulcerative Colitis Therapeutics Market .................................. 65
                                           5.6.1      Drivers for the Ulcerative Colitis Therapeutics Market ............................................. 66
                                           5.6.2      Restraints for the Ulcerative Colitis Therapeutics Market ........................................ 66
                                        5.7     Global Gastroesophageal Reflux Disease (GERD) Therapeutics Market Forecasts ...... 67
                                           5.7.1      Introduction .............................................................................................................. 67
                                           5.7.2      Revenue .................................................................................................................. 68
                                           5.7.3      Generic Share ......................................................................................................... 70
                                           5.7.4      Revenue Analysis by Country.................................................................................. 71
                                           5.7.5      Annual Cost of Treatment........................................................................................ 73
                                           5.7.6      Treatment Flow Algorithm ....................................................................................... 74
                                           5.7.7      Treatment Usage Patterns ...................................................................................... 76
                                        5.8     Major Marleted Products ................................................................................................. 78
                                           5.8.1      Nexium (esomeprazole) .......................................................................................... 78
                                           5.8.2      Aciphex (rabeprazole sodium) ................................................................................. 78
                                           5.8.3      Prevacid (lansoprazole) ........................................................................................... 78
                                           5.8.4      Prilosec (omeprazole) .............................................................................................. 78
                                           5.8.5      Protonix (pantoprazole sodium) ............................................................................... 79
                                           5.8.6      Tagamet (cimetidine) ............................................................................................... 79
                                           5.8.7      Pepcid (famotidine).................................................................................................. 79
                                           5.8.8      Zantac (ranitidine hydrochloride) ............................................................................. 79
                                           5.8.9      Axid (nizatidine) ....................................................................................................... 79
                                        5.9     Drivers and Restraints for the GERD Therapeutics Market............................................. 80
                                           5.9.1      Drivers for the GERD Therapeutics Market ............................................................. 80
                                           5.9.2      Restraints for the GERD Therapeutics Market ........................................................ 80
                                        5.10 Global Crohn’s Disease Therapeutics Market Forecasts ................................................ 81
                                           5.10.1 Introduction .............................................................................................................. 81
                                           5.10.2 Revenue .................................................................................................................. 82
                                           5.10.3 Generic Share ......................................................................................................... 83
                                           5.10.4 Revenue Analysis by Country.................................................................................. 84
                                           5.10.5 Annual Cost of Treatment........................................................................................ 86
                                           5.10.6 Treatment Flow Algorithm ....................................................................................... 87
                                           5.10.7 Treatment Usage Patterns ...................................................................................... 88
                                        5.11 Major Marketed Products ................................................................................................ 90
                                           5.11.1 Remicade (infliximab) .............................................................................................. 90
                                           5.11.2 Humira (adalimumab) .............................................................................................. 90
                                           5.11.3 Tysabri (natalizumab) .............................................................................................. 91
                                           5.11.4 Entocort EC (budenoside) ....................................................................................... 91
                                           5.11.5 Cimzia (cetrolizumab pegol) .................................................................................... 91
                                        5.12 Drivers and Restraints for the Crohn’s Disease Therapeutics Market............................. 92
                                           5.12.1 Drivers for the Crohn’s Disease Therapeutics Market ............................................. 92
                                           5.12.2 Restraints for the Crohn’s Disease Therapeutics Market ........................................ 93
                                      6 Global Gastrointestinal Disorder Therapeutics Market: Pipeline Analysis ................................. 94
                                        6.1     Research and Development Pipeline by Phase .............................................................. 94
                                        6.2     Research and Development Pipeline by Indication ......................................................... 95
                                        6.3     Irritable Bowel Syndrome: Research and Development Pipeline .................................... 96
                                           6.3.1      Overview ................................................................................................................. 96

Gastrointestinal Disorder Therapeutics Market to 2017- Crohn's                                                                        GBIHC131MR / Published SEP 2011
Disease and Irritable Bowel Syndrome Markets Show Strongest
Growth                                                                                                                                                                       Page 5
                                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                           6.3.2    Pipeline by Clinical Phases of Development ........................................................... 97
                                        6.4    Promising Drugs under Clinical Development for Irritable Bowel Syndrome ................... 99
                                           6.4.1    Linaclotide (Linaclotide Acetate) .............................................................................. 99
                                           6.4.2    Asimadoline ........................................................................................................... 100
                                           6.4.3    Xifaxan (Rifaximin) ................................................................................................ 101
                                        6.5    Ulcerative Colitis: Research and Development Pipeline ............................................... 103
                                           6.5.1    Overview ............................................................................................................... 103
                                           6.5.2    Pipeline by Clinical Phases of Development ......................................................... 104
                                        6.6    Promising Drugs under Clinical Development for Ulcerative Colitis .............................. 107
                                           6.6.1    Humira (Adalimumab)............................................................................................ 107
                                           6.6.2    Golimumab ............................................................................................................ 107
                                           6.6.3    Vedolizumab .......................................................................................................... 108
                                        6.7    Crohn’s Disease: Research and Development Pipeline................................................ 109
                                           6.7.1    Overview ............................................................................................................... 109
                                           6.7.2    Pipeline by Clinical Phases of Development ......................................................... 110
                                        6.8    Promising Drugs under Clinical Development for Crohn’s Disease .............................. 113
                                           6.8.1    Myoconda .............................................................................................................. 113
                                           6.8.2    Traficet-EN (CCX282) ........................................................................................... 113
                                           6.8.3    MLN0002 (vedolizumab) ....................................................................................... 114
                                           6.8.4    Prochymal.............................................................................................................. 115
                                           6.8.5    Stelara ................................................................................................................... 115
                                        6.9    Gastroesophageal reflux disease (GERD): Research and Development Pipeline ........ 116
                                           6.9.1    Overview ............................................................................................................... 116
                                           6.9.2    Pipeline by Clinical Phases of Development ......................................................... 117
                                        6.10 Promising Drugs under Clinical Development for GERD .............................................. 118
                                           6.10.1 XP19986................................................................................................................ 118
                                           6.10.2 AZD3355 ............................................................................................................... 119
                                           6.10.3 Rozerem ................................................................................................................ 120
                                           6.10.4 Vecam ................................................................................................................... 120
                                      7 Global Gastrointestinal Disorder Therapeutics Market: Competitive Landscape ..................... 122
                                        7.1    Overview ....................................................................................................................... 122
                                        7.2    Profiles of Major Companies ......................................................................................... 122
                                           7.2.1    AstraZeneca .......................................................................................................... 122
                                           7.2.2    Abbott Laboratories ............................................................................................... 124
                                           7.2.3    Johnson & Johnson ............................................................................................... 125
                                           7.2.4    Salix Pharmaceuticals, Ltd. ................................................................................... 126
                                           7.2.5    Takeda Pharmaceutical Company Limited ............................................................ 128
                                           7.2.6    Pfizer, Inc............................................................................................................... 129
                                           7.2.7    Shire Plc. ............................................................................................................... 130
                                      8 Global Gastrointestinal Disorder Therapeutics Market: Strategic Consolidations .................... 131
                                        8.1    Mergers and Acquisitions (M&A)................................................................................... 131
                                           8.1.1    Overview ............................................................................................................... 131
                                           8.1.2    Major Mergers and Acquisitions Deals .................................................................. 131
                                           8.1.3    Segmentation by Geography ................................................................................. 133
                                           8.1.4    Segmentation by Deal Value ................................................................................. 134
                                           8.1.5    Segmentation by Year ........................................................................................... 135
                                        8.2    Licensing Deals............................................................................................................. 136
                                           8.2.1    Major Licensing Deals ........................................................................................... 136
                                           8.2.2    Segmentation by Geography ................................................................................. 137
                                           8.2.3    Segmentation by Deal Value ................................................................................. 138
                                           8.2.4    Segmentation by Year ........................................................................................... 139
                                        8.3    Co-development Deals ................................................................................................. 140
                                           8.3.1    Major Co-development Deals ................................................................................ 140
                                           8.3.2    Segmentation by Geography ................................................................................. 141
                                           8.3.3    Segmentation by Year ........................................................................................... 142

Gastrointestinal Disorder Therapeutics Market to 2017- Crohn's                                                                     GBIHC131MR / Published SEP 2011
Disease and Irritable Bowel Syndrome Markets Show Strongest
Growth                                                                                                                                                                   Page 6
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                      9   Global Gastrointestinal Disorder Therapeutics Market : Appendix .......................................... 143
                                          9.1    Market Definitions ......................................................................................................... 143
                                          9.2    Abbreviations ................................................................................................................ 143
                                          9.3    Research Methodology ................................................................................................. 144
                                             9.3.1    Coverage ............................................................................................................... 144
                                             9.3.2    Secondary Research ............................................................................................. 145
                                             9.3.3    Primary Research .................................................................................................. 145
                                          9.4    Therapeutic Landscape ................................................................................................ 146
                                             9.4.1    Epidemiology-based Forecasting .......................................................................... 146
                                             9.4.2    Market Size by Geography .................................................................................... 148
                                          9.5    Geographical Landscape .............................................................................................. 149
                                          9.6    Pipeline Analysis ........................................................................................................... 149
                                          9.7    Competitive Landscape ................................................................................................ 149
                                             9.7.1    Expert Panel Validation ......................................................................................... 149
                                          9.8    Contact Us .................................................................................................................... 149
                                          9.9    Disclaimer ..................................................................................................................... 149
                                          9.10 Sources ......................................................................................................................... 150




Gastrointestinal Disorder Therapeutics Market to 2017- Crohn's                                                                       GBIHC131MR / Published SEP 2011
Disease and Irritable Bowel Syndrome Markets Show Strongest
Growth                                                                                                                                                                     Page 7
                                                                                       © GBI Research. This is a licensed product and is not to be photocopied
                                      1.1       List of Tables
                                      Table 1: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($bn), 2002-2010 .... 15
                                      Table 2: Gastrointestinal Disorder Therapeutics Market, Global, Revenue ($bn), 2010-2017 ..... 15
                                      Table 3: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment ($),
                                                2002–2010 ..................................................................................................................... 17
                                      Table 4: Gastrointestinal Disorder Therapeutics Market, Global, Annual Cost of Treatment ($),
                                                2010–2017 ..................................................................................................................... 17
                                      Table 5: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Usage Patterns
                                                (Millions), 2002-2010...................................................................................................... 18
                                      Table 6: Gastrointestinal Disorder Therapeutics Market, Global, Treatment Usage Patterns
                                                (Millions), 2010-2017...................................................................................................... 19
                                      Table 7: Gastrointestinal Disorder Therapeutics Market, Global Revenue by Country ($m), 2002-
                                                2010 ............................................................................................................................... 27
                                      Table 8: Gastrointestinal Disorder Therapeutics Market, Global Revenue by Country ($m), 2010-
                                                2017 ............................................................................................................................... 27
                                      Table 9: Gastrointestinal Disorder Therapeutics Market, The US, Revenue ($bn), 2002-2010 .. 28
                                      Table 10: Gastrointestinal Disorder Therapeutics Market, The US, Revenue ($bn), 2010-2017 .. 28
                                      Table 11: Gastrointestinal Disorder Therapeutics Market, The US, Annual Cost of Treatment ($),
                                                2002-2010 ...................................................................................................................... 29
                                      Table 12: Gastrointestinal Disorder Therapeutics Market, The US, Annual Cost of Treatment ($),
                                                2010-2017 ...................................................................................................................... 29
                                      Table 13: Gastrointestinal Disorder Therapeutics Market, The US, Treatment Usage Patterns
                                                (Millions), 2002-2010...................................................................................................... 30
                                      Table 14: Gastrointestinal Disorder Therapeutics Market, The US, Treatment Usage Patterns
                                                (Millions), 2010-2017...................................................................................................... 31
                                      Table 15: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Revenue
                                                ($bn), 2002-2010............................................................................................................ 32
                                      Table 16: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Revenue
                                                ($bn), 2010-2017............................................................................................................ 32
                                      Table 17: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Revenue
                                                by Country ($m), 2002-2010 .......................................................................................... 33
                                      Table 18: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Revenue
                                                by Country ($m), 2002-2010 .......................................................................................... 34
                                      Table 19: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Annual
                                                Cost of Treatment ($), 2002-2010 .................................................................................. 35
                                      Table 20: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Annual
                                                Cost of Treatment ($), 2010-2017 .................................................................................. 35
                                      Table 21: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Treatment
                                                Usage Patterns (Millions), 2002-2010 ............................................................................ 36
                                      Table 22: Gastrointestinal Disorder Therapeutics Market, Top Five Countries of Europe, Treatment
                                                Usage Patterns (Millions), 2010-2017 ............................................................................ 37
                                      Table 23: Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn), 2002-2010 ..... 38
                                      Table 24: Gastrointestinal Disorder Therapeutics Market, Japan, Revenue ($bn), 2010-2017 ..... 38
                                      Table 25: Gastrointestinal Disorder Therapeutics Market, Japan, Annual Cost of Treatment ($),
                                                2002-2010 ...................................................................................................................... 39
                                      Table 26: Gastrointestinal Disorder Therapeutics Market, Japan, Annual Cost of Treatment ($),
                                                2010-2017 ...................................................................................................................... 39
                                      Table 27: Gastrointestinal Disorder Therapeutics Market, Japan, Treatment Usage Patterns
                                                (Millions), 2002-2010...................................................................................................... 40
                                      Table 28: Gastrointestinal Disorder Therapeutics Market, Japan, Treatment Usage Patterns
                                                (Millions), 2010-2017...................................................................................................... 41
                                      Table 29: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2002-2010..... 43
                                      Table 30: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue ($m), 2010-2017..... 43
                                      Table 31: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m), 2002-
                                                2010 ............................................................................................................................... 45
                                      Table 32: Irritable Bowel Syndrome Therapeutics Market, Global, Revenue by Country ($m), 2010-
                                                2017 ............................................................................................................................... 46
                                      Table 33: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($),
                                                2002-2010 ...................................................................................................................... 47
                                      Table 34: Irritable Bowel Syndrome Therapeutics Market, Global, Annual Cost of Treatment ($),
                                                2010-2017 ...................................................................................................................... 47


Gastrointestinal Disorder Therapeutics Market to 2017- Crohn's                                                                        GBIHC131MR / Published SEP 2011
Disease and Irritable Bowel Syndrome Markets Show Strongest
Growth                                                                                                                                                                       Page 8
                                                                                        © GBI Research. This is a licensed product and is not to be photocopied
                                      Table 35: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns
                                                (Millions), 2002-2010...................................................................................................... 49
                                      Table 36: Irritable Bowel Syndrome Therapeutics Market, Global, Treatment Usage Patterns
                                                (Millions), 2010-2017...................................................................................................... 50
                                      Table 37: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2002-2010 ................... 55
                                      Table 38: Ulcerative Colitis Therapeutics Market, Global, Revenue ($m), 2010-2017 ................... 55
                                      Table 39: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2002-2010 57
                                      Table 40: Ulcerative Colitis Therapeutics Market, Global, Revenue by Country ($m), 2010-2017 58
                                      Table 41: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2002-
                                                2010 ............................................................................................................................... 59
                                      Table 42: Ulcerative Colitis Therapeutics Market, Global, Annual Cost of Treatment ($), 2010-
                                                2017 ............................................................................................................................... 59
                                      Table 43: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2002-
                                                2010 ............................................................................................................................... 62
                                      Table 44: Ulcerative Colitis Therapeutics Market, Global, Treatment Usage Patterns (‘000), 2010-
                                                2017 ............................................................................................................................... 62
                                      Table 45: GERD Therapeutics Market, Global, Revenue ($bn), 2002-2010 .................................. 68
                                      Table 46: GERD Therapeutics Market, Global, Revenue ($bn), 2010-2017 .................................. 68
                                      Table 47: GERD Therapeutics Market, Global, Revenue by Country ($m), 2002-2010 ................. 71
                                      Table 48: GERD Therapeutics Market, Global, Revenue by Country 
				
DOCUMENT INFO
Description: Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth Summary GBI Research’s report, “Gastrointestinal Disorder Therapeutics Market to 2017 - Crohn's Disease and Irritable Bowel Syndrome Markets Show Strongest Growth” provides in-depth analysis of the drivers and barriers that affect the global gastrointestinal disorder therapeutics market. The report analyzes the markets for gastrointestinal disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2017 for the key geographic regions as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets. It is compiled using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. GBI Research finds that the gastrointestinal disorder therapeutics market will decline during the period 2010-2017. This decline will primarily be driven by the negative growth of the gastroesophageal reflux disease (GERD) therapeutics market, which is attributed to the loss of drug patents and the entry of generics. However, other key gastrointestinal markets, such as Crohn’s disease and irritable bowel syndrome therapeutics, will continue to grow due to a strong late stage pipeline that will address unmet needs. The global gastrointestinal disorder therapeutics market is a highly fragmented market, where the big players face stiff competition. The forthcoming patent expiries of major drugs have increased competition, driving the consolidation further. This increasing pressure has also driven companies to enter into licensing agreements. This allows companies to expand their pr
BUY THIS DOCUMENT NOW PRICE: $3500 100% MONEY BACK GUARANTEED
PARTNER GBI Research
GBI Research is a market-leading provider of business intelligence reports. GBI Research covers worldwide markets and issues, supplies actionable data and forecasts and is driven by industry leaders’ insights. GBI Research provides a broad spectrum of reports across the healthcare and energy industries and its online offering is easy to navigate - a comprehensive resource for business information needs. Headquartered in the UK, the company has branches in the US and Asia, and provides world class client support and service.